Zolpidem, triazolam, and temazepam: Behavioral and subject-rated effects in normal volunteers

Journal of Clinical Psychopharmacology

Volumn 16, Issue 2, 1996, Pages 146-157

  Rush, Craig R ^a   Griffiths, Roland R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE RECEPTOR; PLACEBO; TEMAZEPAM; TRIAZOLAM; ZOLPIDEM;

ADULT; ARTICLE; BEHAVIOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; LEARNING; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PERFORMANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADULT; ANTI-ANXIETY AGENTS; AROUSAL; ATTENTION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MENTAL RECALL; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; PYRIDINES; SERIAL LEARNING; TEMAZEPAM; TRIAZOLAM;

EID: 0029881707     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199604000-00007     Document Type: Article

References (50)

1. Sauvanet JP, Langer SZ, Morselli PL. Imidazopyridines in sleep disorders. New York: Raven Press, 1988.
2. Arbilla S, Depoortere H, George P, Lange SZ. Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats. Arch Pharmacol 1985;330:248-51.
3. 1) subtype. J Pharmacol Exp Ther 1988;245:1033-41.
4. Biggio G, Concas A, Corda M, Serra M. Enhancement of GABAergic transmission by zolpidem, an imidazopyridine with preferential affinity for type I benzodiazepine receptors. Eur J Pharmacol 1989;161:173-80.
5. 3H]zolpidem. J Pharmacol Exp Ther 1988;247:309-22.
6. 1-receptor selective imidazopyridine hypnotic zolpidem. Pharmacol Biochem Behav 1988;29:781-3.
7. Byrnes JJ, Greenblatt DJ, Miller LG. Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone. Brain Res Bull 1992;29:905-8.
8. Depoortere H, Zivkovic, B, Lloyd KD, Sanger DJ, Perrault G, Langer SZ, Bartholini G. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 1986;237:649-58.
9. Sanger DJ, Joly D, Zivkovic B. Effects of zolpidem, a new imidazopyridine hypnotic, on the acquisition of conditioned fear in mice: comparison with triazolam and CL 218,872. Psychopharmacology 1986;90:207-10.
10. Perrault G, Morel E, Sanger DJ, Zivkovic B. Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics. Eur J Pharmacol 1990;187:487-94.
11. Cooper SJ, Desa A. Pyrazoloquinolines and zolpidem: effects on hypertonic saline consumption in rehydrating rats. Drug Dev Res 1988;14:161-8.
12. Sanger DJ, Zivkovic B. Further behavioural evidence for the selective sedative action of zolpidem. Neuropharmacology 1988;27: 1125-30.
13. Yerbury RE, Cooper SJ. Novel benzodiazepine receptor ligands: palatable food intake following zolpidem, CGS 17867A, or Ro 23-0364, in the rat. Pharmacol Biochem Behav 1989;33:303-7.
14. Sanger DJ. Further investigation of the stimulus properties of chlordiazepoxide and zolpidem. Agonism and antagonism by two novel benzodiazepines. Psychopharmacology 1987;93:365-8.
15. Sanger DJ, Zivkovic B. Discriminative stimulus properties of chlordiazepoxide and zolpidem. Agonist and antagonist effects of CGS 9896 and ZK 91296. Neuropharmacology 1987;26:499-505.
16. Sanger DJ, Perrault G, Morel E, Joly D, Zivkovic B. The behavioral profile of zolpidem, a novel hypnotic drug of imidazopyridine structure. Physiol Behav 1987;41:235-40.
17. Sanger D, Zivkovic B. Investigation of the development of tolerance to the actions of zolpidem and midazolam. Neuropharmacology 1987;26:1513-8.
18. Cox A, Boyland P, Gent JP, Feely M. An investigation of anticonvulsant tolerance to zolpidem in mice. Br J Pharmacol 1988;95:667P.
19. Perrault G, Morel E, Sanger DJ, Zivkovic B. Differential development of tolerance and dependence after repeated treatment with zolpidem, an imidazopyridirie hypnotic, and benzodiazepine hypnotics. J Psychopharmacol 1990;4:258.
20. VonVoigtlander PF, Lewis RA. A rapid screening method for the assessment of benzodiazepine receptor-related physical dependence in mice: evaluation of benzodiazepine-related agonists and partial agonists. J Pharnracol Methods 1991;26:1-5.
21. Griffiths RR, Sannerud C, Ator NA, Brady JV. Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance, and withdrawal. J Pharmacol Exp Ther 1992;260:1199-1208.
22. Griffiths RR, Lamb RJ, Sannerud CA, Ator NA, Brady JV. Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology 1991;103:154-61.
23. Sannerud C, Cook J, Griffiths RR. Behavioral differentiation of benzodiazepine ligands after repeated administration in baboons. Eur J Pharmacol 1989;167:333-43.
24. Berlin I, Warot D, Hergueta T, Molinier P, Bagot C, Puech AJ. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 1993;13:100-6.
25. Roehrs T, Merlotti L, Zorick F, Roth T. Sedative, memory, and performance effects of hypnotics, Psychopharmacology 1994;116: 130-4.
26. Balkin T, O'Donnell V, Wesensten N, McCann, U, Belenky G. Comparison of the daytime sleep and performance effects of zolpidem versus triazolam. Psychopharmacology 1992;107:83-8.
27. Evans S, Funderburk F, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990;255:1246-55.
28. Kirk T, Roache JD, Griffiths RR. Dose-response evaluation of the amnestic effects of triazolam and pentobarbital in normal subjects. J Clin Psychopharmacol 1990;10:160-7.
29. Rush CR, Higgins ST, Bickel WK, Hughes JR. Acute effects of triazolam and lorazepam on human learning, performance, and subject ratings. J Pharmacol Exp Ther 1993;264:1218-26.
30. Rush CR, Higgins ST, Bickel WK, Hughes JR. A comparison of the acute behavioral effects of triazolam and temazepam in normals. Psychopharmacology 1993;112:407-14.
31. Higgins ST, Stitzer ML. Comparison of the effects of secobarbital and diazepam on the acquisition of response sequences in humans. Drug Dev Res 1990;20:35-42.
32. Roache JD, Griffiths RR. Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability. J Pharmacol Exp Ther 1985;234:120-33.
33. McLeod DR, Griffiths RR, Bigelow GE, Yingling JE. An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instr 1982;14:463-6.
34. Griffiths RR, Bigelow, GE, Liebson I. Differential effects of diazepam and pentobarbital on mood and behavior. Arch Gen Psychiatry 1983;40:865-73.
35. Jasinski D. Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In: Martin WR, ed. Drug addiction I. New York: Springer-Verlag, 1977:197-258.
36. Martin WR, Sloan JW, Sapiro JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971;12:245-58.
37. McNair DM, Lorr M, Dropplemann LF. Profile of Mood States (manual). San Diego: Educational and Industrial Testing Service, 1971.
38. Griffiths RR, Troisi JR II, Silverman K, Mumford GK. Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol 1993;4:3-13.
39. de Wit H, Pierri J, Johanson CE. Reinforcing and subjective effects of diazepam in nondrug-abusing volunteers. Pharmacol Biochem Behav 1989;33:205-13.
40. Mumford GK, Rush CR, Griffiths RR, Abecarnil and alprazolam in humans: Behavioral, subjective and reinforcing effects. J Pharmacol Exp Ther 1995;272:570-80.
41. Mumford GK, Rush CE, Griffiths RR. A comparison of the abuse liability of alprazolam and DN-2327 (pazinaclone) in humans: psychomotor, memory, subjective and reinforcing effects. Exp Clin Psychopharmacology 1995;3:39-48.
42. de Wit H, Uhlenhuth EH, Johanson CE. Drug preference in normal volunteers: effects of age and time of day. Psychopharmacology 1985;87:186-93.
43. de Wit H, Uhlenhuth EH, Johanson CE. Lack of preference for flurazepam in normal volunteers. Pharmacol Biochem Behav 1984; 21:865-9.
44. de Wit H, Johanson CE, Uhlenhuth EH. Reinforcing properties of lorazepam in normal volunteers. Drug Alcohol Depend 1984;13: 31-41.
45. Johanson CE, Uhlenhuth EH, Drug preference and mood in humans: diazepam. Psychopharmacology 1980;71:269-73.
46. Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics: flurazepam, temazepam and triazolam. Arch Gen Psychiatry 1989;46:326-32.
47. Thénot JP, Hermann P, Durand A, Burke JT, Allen J, Garrigou D, Vajta S, Albin H, Thébault JJ, Olive G, Warrington SJ. Pharmacokinetics and metabolism of zoipidem in various animal species and in humans. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders. New York: Raven Press, 1988: 139-53.
48. Bixler E, Kales A, Manfredi RL, Vgontzas AN, Tyson KL, Kales JD. Next-day memory impairment with triazoiam use. Lancet 1991; 337:827-31.
49. Scharf M, Fletcher K, Graham J. Comparative amnestic effects of benzodiazepine hypnotic agents. J Clin Psychiatry 1988;49:134-7.
50. de Wit H, Griffiths RR. Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend 1991;28:83-111.